Biomarkers
Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
Scientific Reports 2022 October 4 [Link] Kui Fan, Chuan-Long Zhang, Bo-Hui Zhang, Meng-Qi Gao, Yun-Chuan Sun Abstract Mesothelioma lies one of the most malignant tumors, in which the identification of the corresponding biomarkers is extremely critical. This study aims to investigate the prognostic value of enhancer homolog 2 (EZH2) mRNA expression in mesothelioma patients accompanied…
Read MoreNew candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin
Tissue & Cell 2022 September 6 [Link] Ozlem Ucer, Nevin Kocaman Abstract Objectives: Malignant mesothelioma (MM) is a primary malignant tumour with a very bad prognosis, which develops from the mesothelial cells lining the serosal surfaces. Because MM can show a wide variety of histological patterns and its cytomorphological features are quite extensive, it is…
Read MoreDefine the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma
Cells 2022 September 19 [Link] Umair Ali Khan Saddozai, Fengling Wang, Saadullah Khattak, Muhammad Usman Akbar, Muhammad Badar, Nazeer Hussain Khan, Lu Zhang, Wan Zhu, Longxiang Xie, Yongqiang Li, Xinying Ji, Xiangqian Guo Abstract Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the availability of invasive biomarkers with promising results, there…
Read MoreSystematic Review, Meta-Analysis and Bioinformatic Analysis of Biomarkers for Prognosis of Malignant Pleural Mesothelioma
Diagnostics 2022 September 12 [Link] Zhenhua Lu, Wenlong Zhang, Ke Huang, Mucheng Zhu, Xiaoting Gu, Defang Wei, Mingxuan Shi, Yaqiong Chen , Huihui Wang Abstract In previous studies, non-invasive diagnostic biomarkers showed great benefit in the early-stage diagnosis of malignant pleural mesothelioma (MPM). However, the accuracy of different biomarkers was controversial. In this study, meta-analysis…
Read MoreExpression of phosphorylated ribosomal protein S6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Modern Pathology 2022 September 17 [Link] Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G Gray, Luca Ampollini, Joachim G Aerts, Emanuela Felley-Bosco, Michaela B Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P Finn, Enrico Silini, Jan von der…
Read MoreIL-7 is expressed in malignant mesothelioma and has a prognostic value
Molecular Oncology 2022 August 28 [Link] Hoa-Le Mai, Sophie Deshayes, Thi-Van-Ha Nguyen, Virginie Dehame, Anne-Laure Chéné, Sophie Brouard, Christophe Blanquart Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted to a small percentage of patients. Thus, a better…
Read MoreMicrobiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma
International Journal of Molecular Sciences 2022 August 12 [Link] Botle Precious Setlai, Zilungile Lynette Mkhize-Kwitshana, Ravi Mehrotra, Thanyani Victor Mulaudzi, Zodwa Dlamini Abstract Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries. According to literature, the incidence of MM is…
Read MoreA combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma
British Journal of Cancer 2022 August 23 [Link] Thinh T Nguyen, Hyun-Sung Lee, Bryan M Burt, Christopher I Amos, Chao Cheng Abstract Background: Malignant pleural mesothelioma (MPM) is a lung pleural cancer with very poor disease outcome. With limited curative MPM treatment available, it is vital to study prognostic biomarkers to categorise different patient risk…
Read MoreArtichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
Journal of Experimental & Clinical Cancer Research 2022 August 20 [Link] Paola Muti, Andrea Sacconi, Claudio Pulito, Giulia Orlandi, Sara Donzelli, Aldo Morrone, James Jiulian, Gerard P Cox, Martin Kolb, Gregory Pond, Peter Kavsak, Mark Norman Levine, Giovanni Blandino, Sabrina Strano Abstract Background: Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure.…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read More